RxDoctor Payments Data

Khon Truong

Family Medicine · Ferndale, WANPI 1841645322

Payments from drug & device makers

$1,523in general payments, 2019–2025

Across 68 payments — averaging $22.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$418
  • Pfizer$239
  • AstraZeneca$168
  • Biohaven Pharmaceuticals, Inc.$150
  • Amgen$110
  • GSK$93
  • plus $345 from 9 others

What the payments were for

  • Food & beverage$1,523100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,523 in reported general payments places this provider in the 85th percentile of 2,275 family medicine providers in Washington.

See all family medicine providers in Washington

Medicare billing

Part B allowed, 2024
$12,141
Medicare patients
126
Services billed
960

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin30$38,508
MounjaroTirzepatide17$19,971
TrulicityDulaglutide11$19,495
OzempicSemaglutide13$18,297
XareltoRivaroxaban21$17,659
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$10,861
Rosuvastatin Calcium80$1,658
Albuterol Sulfate HfaAlbuterol Sulfate48$1,545
Gabapentin90$1,365
Tamsulosin Hcl56$1,040
Duloxetine Hcl45$899
Levothyroxine Sodium80$790
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide57$755
Losartan Potassium64$693
Atorvastatin Calcium97$622

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$15$39,46628 claims
Boehringer IngelheimJardiance$15$38,50830 claims
Novo NordiskOzempic$51$18,29713 claims
GSKTrelegy Ellipta$93$10,86111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,275 family medicine providers in Washington.

Other family medicine in Ferndale

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →